Sergei Chetyrkin
- Molecular Biology
- Clinical Biochemistry top 2%
- Endocrinology, Diabetes and Metabolism top 10%
- Cell Biology top 10%
- Immunology and Allergy top 5%
- Co-authors
- Billy G. HudsonPaul VoziyanNatalia Y. KedishviliVadim PedchenkoOlga V. BelyaevaWendy H. GoughAmy‐Joan L. HamAaron L. Fidler
- Topics
- Advanced Glycation End Products research (9 papers)Cell Adhesion Molecules Research (5 papers)Chronic Kidney Disease and Diabetes (4 papers)
- Partner nations
- United StatesAustraliaGermany
In The Last Decade
Sergei Chetyrkin
26 papers receiving 1.1k citations
Peers
Comparison fields: 5 of 99
- Molecular Biology 489
- Clinical Biochemistry 233
- Endocrinology, Diabetes and Metabolism 198
- Cell Biology 189
- Immunology and Allergy 133
Countries citing papers authored by Sergei Chetyrkin
This map shows the geographic impact of Sergei Chetyrkin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sergei Chetyrkin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sergei Chetyrkin more than expected).
Fields of papers citing papers by Sergei Chetyrkin
This network shows the impact of papers produced by Sergei Chetyrkin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sergei Chetyrkin. The network helps show where Sergei Chetyrkin may publish in the future.
Co-authorship network of co-authors of Sergei Chetyrkin
This figure shows the co-authorship network connecting the top 25 collaborators of Sergei Chetyrkin. A scholar is included among the top collaborators of Sergei Chetyrkin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sergei Chetyrkin. Sergei Chetyrkin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 3 | |
| 2 | 0 | |
| 3 | 4 | |
| 4 | 86 | |
| 5 | 9 | |
| 6 | 131 | |
| 7 | 11 | |
| 8 | 27 | |
| 9 | 57 | |
| 10 | 9 | |
| 11 | 65 | |
| 12 | 34 | |
| 13 | 41 | |
| 14 | 67 | |
| 15 | 7 | |
| 16 | 21 | |
| 17 | 6 | |
| 18 | 60 | |
| 19 | 55 | |
| 20 | 72 |
About Sergei Chetyrkin
Sergei Chetyrkin is a scholar working on Clinical Biochemistry, Immunology and Allergy and Nephrology, having authored 27 papers that have together received 1.1k indexed citations. Recurring topics across this work include Advanced Glycation End Products research (9 papers), Cell Adhesion Molecules Research (5 papers) and Chronic Kidney Disease and Diabetes (4 papers). The work is most often cited by research in Clinical Biochemistry (233 citations), Immunology and Allergy (133 citations) and Endocrinology, Diabetes and Metabolism (198 citations). Sergei Chetyrkin has collaborated with scholars based in United States, Australia and Germany. Frequent co-authors include Billy G. Hudson, Paul Voziyan, Natalia Y. Kedishvili, Vadim Pedchenko, Olga V. Belyaeva, Wendy H. Gough, Amy‐Joan L. Ham, Aaron L. Fidler, Kyle L. Brown and David L. Hachey. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Biochemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.